Figure 2. Patient-reported outcomes (PROs) in patients who developed arthritis. PRO scores for health assessment questionnaire disability index (HAQ-DI) score, EuroQol five dimension (EQ-5D) questionnaire, visual analogue scale (VAS) pain, physical component score (PCS) and mental component score (MCS) of the 36-item short-form heath survey (SF-36) questionnaire, stratified for treatment (n placebo (PBO)=14; n rituximab (RTX)=12) at baseline and arthritis visit are shown for patients who developed rheumatoid arthritis (RA) within the study period. Median (IQR) time of RA onset was 12.0 (2.0–15.0) months in the PBO group and 16.5 (9.75–28.0) in the RTX group (PBO=red line; RTX=blue line).